ProShare Advisors LLC Has $116,000 Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

ProShare Advisors LLC raised its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 36.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 14,289 shares of the company’s stock after acquiring an additional 3,804 shares during the period. ProShare Advisors LLC’s holdings in Phathom Pharmaceuticals were worth $116,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in PHAT. Jennison Associates LLC lifted its holdings in shares of Phathom Pharmaceuticals by 20.4% in the 4th quarter. Jennison Associates LLC now owns 7,062,507 shares of the company’s stock worth $57,348,000 after purchasing an additional 1,196,118 shares in the last quarter. Vanguard Group Inc. raised its holdings in Phathom Pharmaceuticals by 3.1% during the fourth quarter. Vanguard Group Inc. now owns 2,779,561 shares of the company’s stock worth $22,570,000 after buying an additional 83,238 shares during the last quarter. Wasatch Advisors LP lifted its stake in shares of Phathom Pharmaceuticals by 531.3% in the fourth quarter. Wasatch Advisors LP now owns 1,558,928 shares of the company’s stock valued at $12,658,000 after buying an additional 1,311,986 shares in the last quarter. Catalys Pacific LLC grew its holdings in shares of Phathom Pharmaceuticals by 4.0% during the fourth quarter. Catalys Pacific LLC now owns 1,167,114 shares of the company’s stock valued at $9,477,000 after buying an additional 44,542 shares during the last quarter. Finally, 683 Capital Management LLC grew its holdings in shares of Phathom Pharmaceuticals by 1.5% during the fourth quarter. 683 Capital Management LLC now owns 1,025,000 shares of the company’s stock valued at $8,323,000 after buying an additional 15,000 shares during the last quarter. Institutional investors and hedge funds own 99.01% of the company’s stock.

Phathom Pharmaceuticals Stock Performance

NASDAQ:PHAT opened at $4.64 on Tuesday. Phathom Pharmaceuticals, Inc. has a 52 week low of $2.21 and a 52 week high of $19.71. The firm has a 50-day moving average price of $4.17 and a two-hundred day moving average price of $5.96. The firm has a market cap of $323.94 million, a price-to-earnings ratio of -0.82 and a beta of 0.15.

Analyst Ratings Changes

PHAT has been the topic of a number of analyst reports. Craig Hallum restated a “buy” rating on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. HC Wainwright lowered their price objective on Phathom Pharmaceuticals from $28.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Monday, April 21st. Guggenheim cut their target price on Phathom Pharmaceuticals from $18.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group lowered their price target on Phathom Pharmaceuticals from $10.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, May 2nd. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $17.60.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.